• Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

  • 2022/06/16
  • 再生時間： 2 分
  • ポッドキャスト

Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • EMPRISE is a 5-year monitoring program that uses Medicare and two commercial claims in the United States to assess the efficacy and safety of empagliflozin (EMPA). A total of 190,226 type 2 diabetes patients aged 18 years or older who started EMPA or a dipeptidyl peptidase-4 inhibitor (DPP-4i) and were followed for heart failure hospitalization in primary or any discharge position a composite of MI and stroke, and all-cause mortality (ACM). Safety outcomes were lower-limb amputations (LLA), non-vertebral fractures, diabetic ketoacidosis (DKA), acute kidney injury (AKI), renal and bladder cancers.

    EMPA was linked to a lower risk of hospitalization for heart failure, a similar risk of MI or stroke, and a lower risk of all-cause mortality when compared to DPP4i. EMPA was associated with lower risk of acute kidney injury, higher risk of diabetic ketoacidosis, and a similar risk of lower-limb amputations, fractures, and renal and bladder cancer.

    In conclusion, these findings back up EMPA's cardiovascular effectiveness in normal treatment, with a safety profile that matches recorded data.
    続きを読む 一部表示
activate_samplebutton_t1

あらすじ・解説

EMPRISE is a 5-year monitoring program that uses Medicare and two commercial claims in the United States to assess the efficacy and safety of empagliflozin (EMPA). A total of 190,226 type 2 diabetes patients aged 18 years or older who started EMPA or a dipeptidyl peptidase-4 inhibitor (DPP-4i) and were followed for heart failure hospitalization in primary or any discharge position a composite of MI and stroke, and all-cause mortality (ACM). Safety outcomes were lower-limb amputations (LLA), non-vertebral fractures, diabetic ketoacidosis (DKA), acute kidney injury (AKI), renal and bladder cancers.

EMPA was linked to a lower risk of hospitalization for heart failure, a similar risk of MI or stroke, and a lower risk of all-cause mortality when compared to DPP4i. EMPA was associated with lower risk of acute kidney injury, higher risk of diabetic ketoacidosis, and a similar risk of lower-limb amputations, fractures, and renal and bladder cancer.

In conclusion, these findings back up EMPA's cardiovascular effectiveness in normal treatment, with a safety profile that matches recorded data.
続きを読む 一部表示

Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Studyに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。